Prescription drug · NDA
Yutrepia (Treprostinil) NDC 72964-011
Treprostinil sodium 26.5 ug/1 · Capsule · Respiratory (Inhalation) · Liquidia Technologies, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72964-011-01 | 72964001101 | 7 BLISTER PACK in 1 CARTON (72964-011-01) / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULEMarketed from May 23, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Yutrepia
- Generic name (nonproprietary)
- treprostinil
- Active ingredients
- Treprostinil sodium — 26.5 ug/1
- Dosage form
- Capsule
- Route
- Respiratory (Inhalation)
- Labeler
- Liquidia Technologies, Inc.NDC labeler code 72964
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 213005
- Marketing start
- Listing expires
- Other FDA classes
- Prostaglandins I (Chemical structure)Vasodilation (Physiologic effect)
- Identifiers
- Product ID 72964-011_92c4515d-7de1-4bde-9ee9-f350696ba98dSPL ID 92c4515d-7de1-4bde-9ee9-f350696ba98dSPL set ID e8f6d534-115c-440e-bdbb-b443a29bb468RxCUI 2714659, 2714664, 2714666, 2714668, 2714670, 2714672, 2714674, 2714676UNII 7JZ75N2NT6
- Pharmacologic class
- Prostacycline Vasodilator
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N472964001101followed by a unit qualifier and the quantityPackage 72964-0011-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
• Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue di…
Excerpt only. Read the full label for complete information.
About NDC 72964-011
- What is NDC 72964-011?
- 72964-011 is the product NDC for Yutrepia (treprostinil), Treprostinil sodium 26.5 ug/1 capsule, listed with the FDA by Liquidia Technologies, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Yutrepia (Treprostinil).
- What is the active ingredient?
- Treprostinil sodium.
- Who is the labeler?
- Liquidia Technologies, Inc., NDC labeler code 72964. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Yutrepia?
- 3 other product NDCs are listed under this name. See all Yutrepia NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Yutrepia products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Yutrepiatreprostinil | Treprostinil sodium 53 ug/1 | CapsuleRespiratory (Inhalation) | Liquidia Technologies, Inc. | 72964-012 | 72964-0012-01 |
| Yutrepiatreprostinil | Treprostinil sodium 79.5 ug/1 | CapsuleRespiratory (Inhalation) | Liquidia Technologies, Inc. | 72964-013 | 72964-0013-01 |
| Yutrepiatreprostinil | Treprostinil sodium 106 ug/1 | CapsuleRespiratory (Inhalation) | Liquidia Technologies, Inc. | 72964-014 | 72964-0014-01 |
Other NDCs under NDA 213005
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Yutrepiatreprostinil | Treprostinil sodium 53 ug/1 | CapsuleRespiratory (Inhalation) | Liquidia Technologies, Inc. | 72964-012 |
| Yutrepiatreprostinil | Treprostinil sodium 79.5 ug/1 | CapsuleRespiratory (Inhalation) | Liquidia Technologies, Inc. | 72964-013 |
| Yutrepiatreprostinil | Treprostinil sodium 106 ug/1 | CapsuleRespiratory (Inhalation) | Liquidia Technologies, Inc. | 72964-014 |